Literature DB >> 31201711

Remogliflozin Etabonate: First Global Approval.

Anthony Markham1.   

Abstract

Remogliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remogliflozin etabonate (Remo™, Remozen™), the prodrug for remogliflozin, recently received its first approval as a treatment for type 2 diabetes mellitus (T2DM) in India. This article summarizes the milestones in the development of remogliflozin etabonate leading to this first approval for T2DM.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31201711     DOI： 10.1007/s40265-019-01150-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.

Authors:  Robin O'Connor-Semmes; Susan Walker; Anita Kapur; Elizabeth K Hussey; June Ye; Laurene Wang-Smith; Wenli Tao; Robert L Dobbins; Bentley Cheatham; William O Wilkison
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

2.  Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.

Authors:  A P Sykes; R O'Connor-Semmes; R Dobbins; D J Dorey; J D Lorimer; S Walker; W O Wilkison; L Kler
Journal:  Diabetes Obes Metab       Date:  2014-11-03       Impact factor: 6.577

3.  Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice.

Authors:  Shigeru Nakano; Kenji Katsuno; Masayuki Isaji; Tatsuya Nagasawa; Benjamin Buehrer; Susan Walker; William O Wilkison; Bentley Cheatham
Journal:  J Clin Exp Hepatol       Date:  2015-04-28

4.  Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.

Authors:  A P Sykes; G L Kemp; R Dobbins; R O'Connor-Semmes; S R Almond; W O Wilkison; S Walker; L Kler
Journal:  Diabetes Obes Metab       Date:  2014-11-03       Impact factor: 6.577

5.  Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Authors:  Yoshikazu Fujimori; Kenji Katsuno; Ikumi Nakashima; Yukiko Ishikawa-Takemura; Hideki Fujikura; Masayuki Isaji
Journal:  J Pharmacol Exp Ther       Date:  2008-06-26       Impact factor: 4.030

6.  Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Authors:  Elizabeth K Hussey; Anita Kapur; Robin O'Connor-Semmes; Wenli Tao; Bryan Rafferty; Joseph W Polli; Charles D James; Robert L Dobbins
Journal:  BMC Pharmacol Toxicol       Date:  2013-04-30       Impact factor: 2.483

7.  First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.

Authors:  Anita Kapur; Robin O'Connor-Semmes; Elizabeth K Hussey; Robert L Dobbins; Wenli Tao; Marcus Hompesch; Glenn A Smith; Joseph W Polli; Charles D James; Imao Mikoshiba; Derek J Nunez
Journal:  BMC Pharmacol Toxicol       Date:  2013-05-13       Impact factor: 2.483
  7 in total
  5 in total

Review 1.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

Review 2.  Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.

Authors:  Viswanathan Mohan; Ambrish Mithal; Shashank R Joshi; S R Aravind; Subhankar Chowdhury
Journal:  Drug Des Devel Ther       Date:  2020-06-24       Impact factor: 4.162

3.  Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness.

Authors:  Mahesh Attimarad; Anroop B Nair; Nagaraja Sreeharsha; Bandar E Al-Dhubiab; Katharigatta N Venugopala; Pottathil Shinu
Journal:  Int J Environ Res Public Health       Date:  2021-01-08       Impact factor: 3.390

4.  Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation.

Authors:  Mahesh Attimarad; Katharigatta N Venugopala; Bandar E Al-Dhubiab; Rafea Elamin Elgack Elgorashe; Sheeba Shafi
Journal:  Molecules       Date:  2021-10-12       Impact factor: 4.411

Review 5.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.